Orphan Drug Designation
- Health
U.S. Food & Drug Administration Grants Priority Review of Maribavir for the Treatment of Post-Transplant Recipients With Cytomegalovirus Infection in Those Resistant and/or Refractory to Prior Anti-CMV Treat
Osaka, Japan: − If Approved, Maribavir Will Be the First and Only Treatment Indicated for Post-Transplant Cytomegalovirus (CMV) Infection in…
Read More » - Health
Orphan Drug Designation Granted to Rezafungin in EU for the Treatment of Invasive Candidiasis
Cambridge, United Kingdom & San Diego, United States: Invasive candidiasis (IC) is characterised as a severe, life-threatening Candida infection of the bloodstream…
Read More »